



## Ancillary Studies Policy

### Appendix A: Core and Ancillary Data to Date

*As of: June 20, 2016*

The tables below include lists of data acquisitions approved by the CureGN Steering Committee. As noted in the tables, these lists include data for studies that are funded and those that are under review. For data collected as part of the core CureGN protocol, please see the [Data Element Categories](#) and [Biospecimens List](#) on the CureGN Study Website

The following data are approved as CureGN “Core Data.” This list will be updated over time:

<b>Core Data</b>	<b>Diagnoses to be studied (FSGS, MCD, MN, IgAN)</b>	<b>Date of SC approval as core data</b>	<b>Funding mechanism (corresponding PI)</b>	<b>Funding status</b>
“Core” pathology scoring, via DPR	All	9/23/2015	NIDDK supplement	Funded 09/03/2015
Genome-wide SNP arrays (Global MEGA Power Chip), Replicate and finemap all known susceptibility loci across different glomerular disease types, PBL RNAseq gene expression data for all 2400 CureGN participants, expression QTL analysis for each disease type	All	9/29/2015	NIDDK ancillary study (Kirylyuk)	Under review
Proteomics will be performed on 600 blood samples from the CureGN biorepository by LC-MS, data analyzed by Sequest and Matrix Science Mascot algorithms, and the data aggregated with respect to high probability/high confidence peptide/protein assignments using Scaffold3.	All	9/29/2015	NIDDK ancillary study (Smoyer)	Under review
Metabolomics will be performed on 600 blood samples from the CureGN biorepository using NMR metabolomics, and the data analyzed by statistical and multivariate analysis after alignment, formatting, and normalization.	All	9/29/2015	NIDDK ancillary study (Smoyer)	Under review

<b>Core Data</b>	<b>Diagnoses to be studied (FSGS, MCD, MN, IgAN)</b>	<b>Date of SC approval as core data</b>	<b>Funding mechanism (corresponding PI)</b>	<b>Funding status</b>
Testing for non-inferiority of WSI to GS for diagnosis and scoring utilizing suitable CureGN biopsy materials.	All	9/29/2015	NIDDK ancillary study (Nachman)	Under review
ELISA analysis will be performed according to published methods validated in smaller cohorts, i.e. IgG and IgA glycan specific autoantibodies, sCD89-IgA complex, serum C3 and serum IgA (routine clinical tests). ELLA: Serum galactose-deficient IgA1 (Gd-IgA1) concentration will be estimated using a well-validated lectin-based assay that uses N-Acetylgalactosamine (GalNAc)-specific <i>Helix aspersa</i> lectin. In addition, we developed a rapid and simple lectin-based assay for monitoring changes in immunoglobulin sialylation using <i>Sambucus nigra</i> agglutinin (SNA). This assay will be used to estimate serum sialic acid-deficient (Sd-IgA1) concentration. High Resolution Mass Spectrometry (MS) (electrospray ionization-Q-time-of-flight and Orbitrap-based liquid chromatography-mass spectrometry) will be used.	IgAN	9/29/2015	NIDDK ancillary study (Nachman)	Under review
Whole exome sequencing (WES) coupled with high-density DNA microarrays: Illumina SNP genotyping	MCD, FSGS	12/21/2015	NIDDK ancillary study (Sanna-Cherchi)	Under review

The following data are approved as CureGN “Ancillary Data.” This list will be updated over time:

<b>Ancillary Data</b>	<b>Diagnoses to be studied (FSGS, MCD, MN, IgAN)</b>	<b>Date of SC approval as ancillary data</b>	<b>Funding mechanism (corresponding PI)</b>	<b>Funding status</b>
Throat microbiome rRNA sequencing	IgAN	9/1/2015	CIHR (Reich)	Under review
ECHO NEPTUNE/CureGN – Evaluating Childhood Cardiovascular Health Outcomes in NEPTUNE and CureGN	FSGS, MCD	4/12/2016	American Heart Association Grant-in-Aid (Sethna)	Funded